Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts
- Munderi, P.
- Walker, A. S.
- Kityo, C.
- Babiker, A. G.
- Ssali, F.
- Reid, A.
- Darbyshire, J. H.
- Grosskurth, H.
- Mugyenyi, P.
- Gibb, D. M.
- Gilks, C. F.
- DART/NORA Trial Teams
DOIAbstract
Background: Triple nucleoside reverse transcriptase inhibitor regimens have advantages as first-line antiretroviral therapy (ART), avoiding hepatotoxicity and interactions with anti-tuberculosis therapy, and sparing two drug classes for second-line ART. Concerns exist about virological potency; efficacy has not been assessed in Africa. Methods:A safety trial comparing nevirapine with abacavir was conducted in two Ugandan Development of Antiretroviral Therapy in Africa (DART) centres: 600 symptomatic antiretroviral-naïve HIV-infected adults with CD4 count
Add to ORKG